Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
581-600 of 1,738 trials

Advanced Solid Tumors: D3S-001 Treatment Study

We are testing the safety and tolerability of D3S-001, alone or with other cancer medicines, for adults with advanced solid tumors that have a KRAS p.G12C mutation. This study aims to understand how the treatment works and its effects on tumors.

Advanced Solid Tumors with a KRAS p.G12C MutationSafety phase (I)Efficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

PIK3CA-Related Overgrowth Spectrum: Alpelisib Study

We are investigating whether the medication alpelisib is safe and effective for individuals with PIK3CA-related overgrowth spectrum. This study includes both children and adults to assess its impact on their symptoms and overall health.

PIK3CA-Related Overgrowth Spectrum6-12 monthsEfficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineOncology

Ravulizumab for Children with NMOSD

We are studying the safety and effectiveness of Ravulizumab in children and adolescents with NMOSD. This trial aims to see how it affects their neurological function and overall quality of life.

Neuromyelitis Optica Spectrum Disorder1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Cirrhosis and Portal Hypertension: Metformin Study

We are investigating whether metformin can improve liver blood flow in patients with cirrhosis and portal hypertension. This study will also assess the safety of metformin and its effects on liver health.

Portal Hypertension1-2 yearsEfficacy phase (II)≤5 visitsStandard MedicinesHepatologyInternal Medicine

Advanced Head and Neck Cancer: TG4050 Gene Therapy

We are testing a personalized gene therapy for patients with advanced head and neck cancer. The goal is to see if it can improve treatment outcomes compared to standard options.

Head and Neck Squamous Cell Carcinoma>2 yearsSafety phase (I)Efficacy phase (II)OncologyOtolaryngology

High-Risk Neuroblastoma: Naxitamab and GM-CSF Treatment

We are studying a new treatment combining naxitamab and GM-CSF for children with high-risk neuroblastoma who have not responded to prior therapies. The trial aims to assess how well this treatment works and its safety.

Recurrent Neuroblastoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncologyPediatrics

Multiple Myeloma: AZD0305 Treatment Study

We are investigating whether AZD0305, alone or with other cancer therapies, is safe and effective for adults with relapsed or refractory multiple myeloma.

Relapsed or Refractory Multiple MyelomaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Pancreatic Cancer: Gembrax with Folfirinox

We are studying whether adding Gembrax to the standard Folfirinox treatment helps patients with metastatic pancreatic cancer. This trial aims to find out if the combination is more effective than Folfirinox alone.

Metastatic Pancreatic Cancer>2 yearsEfficacy phase (II)GastroenterologyOncology

Preventing Blood Clots: REGN9933 and REGN7508 Study

We are studying two new medications to see if they can help prevent blood clots in adults with a peripherally inserted central catheter. The trial will also assess how safe these treatments are.

Venous Thromboembolism3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyHematology

Hyponatremia: Empagliflozin Treatment Study

We are investigating whether empagliflozin can help increase sodium levels in patients with euvolemic or hypervolemic hyponatremia. The study will also look at its effects on related symptoms and overall health.

Low Sodium Levels (Hyponatremia)≤3 monthsEfficacy phase (II)≤5 visitsStandard MedicinesEndocrinologyInternal Medicine

Graft-Versus-Host Disease: Corticosteroids with ECP

We are studying whether adding extracorporeal photopheresis to corticosteroids helps patients with Grade II acute graft-versus-host disease after stem cell transplantation. This trial compares treatment outcomes and side effects between the two approaches.

Acute Graft-Versus-Host Disease (GVHD)>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

BRAF V600E Mutated Metastatic Colorectal Cancer: ENCORAFENIB and FOLFIRI

We are studying a combination of ENCORAFENIB and FOLFIRI for patients with BRAF V600E mutated metastatic colorectal cancer that has progressed on previous treatments. The goal is to see if this combination can improve treatment outcomes and safety.

Colorectal Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

HIV and HBV Co-Infection: Antiviral Treatment Strategies

We are studying two treatment reduction strategies for patients co-infected with HIV-1 and HBV to see how safely they can manage their viral infections. The trial will also look at the impact on quality of life and any potential side effects.

Co-infection with HIV-1 and HBV>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesHepatologyInfectious Diseases

Patellofemoral Osteoarthritis: Nasal Cartilage Implant Study

We are investigating whether a new treatment using engineered nasal cartilage can help reduce pain and improve knee function in people with osteoarthritis behind the kneecap. This study compares the new approach to standard treatments.

Knee OsteoarthritisPatellofemoral Osteoarthritis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesInternal MedicineOrthopedics and Traumatology

Cytomegalovirus in Pregnancy: Valacyclovir Study

We are comparing the effectiveness and safety of valacyclovir for treating primary cytomegalovirus infection in pregnant women. The study looks at how different doses may impact treatment outcomes and safety.

CMV Infection6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesGynecology and ObstetricsInfectious Diseases

Advanced Solid Tumors: PM54 Treatment

We are testing a new treatment called PM54 for patients with advanced solid tumors. The goal is to evaluate its safety and how well it works compared to existing options.

Advanced Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Melanoma Treatment: LTX-315 and Pembrolizumab

We are studying a new treatment combination for patients with resectable stage III-IV melanoma. The goal is to see how well it shrinks tumors and affects overall health and quality of life.

Stage III Malignant Melanoma≤3 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesDermatologyOncology

Systemic Lupus Erythematosus: SAR441344 Treatment Study

We are investigating a new medication for people with Systemic Lupus Erythematosus to see if it helps reduce disease activity and improve symptoms compared to a placebo.

Systemic Lupus Erythematosus6-12 monthsEfficacy phase (II)16-20 visitsInvestigational MedicinesPartially RemoteInternal MedicineRheumatology

Colorectal Cancer: PD L 506 Oral Medication Study

We are investigating the safety of a new oral medication for patients with colorectal cancer and healthy volunteers. The study also looks at whether urine tests can help in diagnosing colorectal cancer.

Colorectal Cancer6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInternal MedicineOncology

C3 Glomerulopathy and ICGN: OMS906 Study

We are testing a new drug called OMS906 in patients with C3 Glomerulopathy or Idiopathic Immune Complex-Mediated Glomerulonephritis. The study aims to evaluate the safety and early effects of this treatment on kidney function.

Immune Complex Glomerulonephritis6-12 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesNephrology